/

OTLK

Outlook Therapeutics, Inc.Closed

0.5638−0.02 −3.64%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.5600 −0.67%

Open

0.5788

Prev close

0.5851

Day range

0.55100.5812

52-week range

0.16102.54

Volume

3.24M0.25×

Mkt cap

137.26M

P/E ttm

—

Fwd P/E

-4.70

EPS ttm

-0.7000

Div yield

0.00%

Earnings

Aug 14, 2026

From 52w high

−77.79%

Price Chart

Yahoo Finance · delayed

OTLKOct 13, 2026O 0.5790H 0.5810L 0.5510C 0.5640−0.0210 (−3.59%)Vol 3.25M

SMA 500.7015
SMA 2000.6916

1Y change −56.95% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

OTLK Outlook Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.40%
1 month: −14.55%
3 months: −67.40%
6 months: +122.92%
Year to date: −64.30%
1 year: −56.95%

Valuation & ownership

Market cap: 137.26M
Enterprise value: 144.44M
P/E (ttm): —
Forward P/E: -4.70
PEG ratio: —
Price / book: —
Price / sales (ttm): -117.97
EV / EBITDA: -2.60
EPS (ttm): -0.7000
EPS (forward): -0.1200
Beta (5y monthly): 0.67
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 243.45M
Float: 197.82M
Short % of float: 13.88%
Short ratio (days): 7.10
Held by insiders: 12.64%
Held by institutions: 16.70%
Avg volume (3m): 13.12M
50-day average: 0.7085
200-day average: 0.6980
52-week change: −56.95%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.5
vs 50-day SMA: −19.60%
vs 200-day SMA: −18.45%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.46%
Realised vol (20d, ann.): 58.5%
From 52-week high: −77.78%
From 52-week low: +250.31%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

5.03

+791.27% implied

Low 1.60Median 4.00High 10.50

Recommendation trend

Now3 / 1 / 0
1m ago3 / 1 / 0
2m ago

DES

About Outlook Therapeutics, Inc.

Yahoo Finance profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Iselin, NJ, United States
Website: outlooktherapeutics.com
Officers: Mr. Robert Charles Jahr President, CEO & Director
Mr. Kevin Lundquist CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mr. Joel Prieve Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D. Senior Vice President of Medical Affairs

SEAS

Seasonality · OTLK

2016–2026 · monthly returns

Strongest month Oct +17.70%Weakest month Aug −17.86%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-72.2	-4.3	-51.1	21.4	192.0	117.8	-38.6	-35.2	-9.3	-1.8			−64.3%
2025	9.0	-27.2	-18.7	28.7	17.2	-13.0	22.5	-56.6	24.6	18.9	42.1	-11.7	−16.4%
2024	-2.0	13.2	36.6	-25.3	-20.7	4.4	5.0	-5.2	-27.3	7.9	-64.4	-7.8	−76.0%
2023	6.5	-5.2	0.0	-3.7	42.9	16.0	-0.6	-86.8	-3.1	171.5	-20.0	-17.9	−63.5%
2022	4.4	14.8	9.2	-12.9	-25.8	-11.3	10.8	-0.9	8.9	-4.9	-10.3	3.8	−20.6%
2021	-28.1	132.1	3.7	5.8	12.6	-7.1	-9.2	22.1	-21.4	-4.6	-27.1	-9.9	+4.6%
2020	56.6	-17.7	-20.9	12.3	51.1	26.5	5.4	-51.5	9.1	8.3	53.8	8.3	+120.3%
2019	53.0	45.1	-16.7	-83.0	90.5	-13.3	12.0	-34.3	-2.6	-12.1	-20.6	-43.3	−85.2%
2018	-12.3	0.0	-21.9	2.4	3.2	-10.1	0.6	1.9	13.2	1.0	-35.2	-22.1	−61.5%
2017	18.3	-10.4	-16.0	-16.4	-32.1	-34.2	0.0	-13.2	57.8	-8.0	-2.4	5.7	−56.8%
2016							-4.4	45.8	-10.3	-0.9	-18.5	-12.2	−11.5%

INSD

Insider Activity · OTLK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 13, 2026	Kenyon Lawrence A.Chief Financial Officer	Purchase at price 0.76 per share.	101K	$76.40K
Aug 13, 2026	Jahr Robert CharlesChief Executive Officer	Purchase at price 0.76 per share.	151.5K	$114.61K
Aug 11, 2026	Sukhtian Ghiath MBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.99 per share.	2.53M	$2.50M
Jul 28, 2026	Sukhtian Faisal GhiathDirector	Purchase at price 1.05 per share.	95.4K	$100.00K
Jun 1, 2026	Haddadin Yezan MuntherDirector	Purchase at price 0.83 per share.	29K	$24.14K
May 26, 2026	Sukhtian Faisal GhiathDirector	Purchase at price 0.59 per share.	122.2K	$71.53K
May 25, 2026	Hilzinger Kurt JDirector	Purchase at price 0.44 per share.	400K	$176.52K
May 25, 2026	Thurman Randy HDirector	Purchase at price 0.43 per share.	5K	$2.15K
May 25, 2026	Haddadin Yezan MuntherDirector	Purchase at price 0.44 per share.	34K	$14.96K
May 26, 2025	Sukhtian Ghiath MDirector and Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 1.40 per share.	4.29M	$6.00M
Jan 16, 2025	Sukhtian Ghiath MDirector and Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 2.23 per share.	3.46M	$7.71M
Jan 16, 2025	Sukhtian Ghiath MDirector and Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 2.51 per share.	3.46M	$8.68M

OTLK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

OTLK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Outlook Therapeutics, Inc.

Seasonality · OTLK

Insider Activity · OTLK

Congress Trades · OTLK

Investors Holding OTLK

Investors Holding OTLK

Congress Trades · OTLK

Insider Activity · OTLK

Seasonality · OTLK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Outlook Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News